tirzepatide compound news today FDA declares shortage over for popular weight-loss, diabetes drug Compounded Tirzepatide - HelloWellness

Semaglutide is a once-weekly subcutaneous injection to target weight loss and control, as well as appetite suppression

Tirzepatide is emerging as a significant player in the management of Type 2 diabetes and obesity, endorsed by the FDA and characterized by a distinctive mechanism of action that sets it apart from other GLP-1 agonists

You inject it just under the skin once a week, on any day that suits your routine, using a simple pen that holds a single dose

This enhanced sense of fullness makes balanced eating more achievable while curbing overindulgence

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes management and chronic weight management in adults with obesity or overweight with weight-related comorbidities